https://www.regulatoryrapporteur.org/january-2022-contents/541.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/april-2022-contents/528.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/june-2022-contents/525.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/interviews/building-best-regulatory-practices-in-brazil/31.article 2024-02-14T14:36:02.417Z https://www.regulatoryrapporteur.org/meetings-reports/the-emas-veterinary-big-data-stakeholder-forum-part-2/32.article 2024-02-14T14:36:02.417Z https://www.regulatoryrapporteur.org/main-navigation/conditional-oncology-drug-approvals-a-sponsors-perspective-on-the-evolving-landscape-of-fda-accelerated-approvals/24.article 2024-02-14T14:36:02.417Z https://www.regulatoryrapporteur.org/medical-devices/new-regulatory-tools-for-drug-developers-sharing-experience/27.article 2025-08-11T15:03:24.660Z https://www.regulatoryrapporteur.org/pharmaceuticals/time-is-running-out-for-the-rare-pediatric-disease-designation-and-priority-review-voucher-programs/30.article 2024-02-14T14:36:02.417Z https://www.regulatoryrapporteur.org/editorials/regulatory-support-for-drug-development-maximising-options-for-timely-patient-access/25.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/selection-and-justification-of-regulatory-starting-materials/26.article 2024-02-14T14:36:02.417Z https://www.regulatoryrapporteur.org/february-2022-contents/540.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/interviews/a-strong-advocate-for-global-harmonisation-in-animal-health/17.article 2024-02-14T14:36:50.823Z https://www.regulatoryrapporteur.org/main-navigation/pharmacovigilance-regulations-post-brexit/18.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/veterinary/hype-over-hemp-as-a-veterinary-feed-additive/23.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/brexit--regulatory-and-supply-chain-considerations/21.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/the-impact-of-the-northern-ireland-protocol-on-human-medicines/16.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/editorials/the-uk-and-brexit-innovation-and-optimism-in-uncertain-times/14.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-devices/a-review-of-project-orbis-an-initiative-enabling-faster-patient-access-to-cancer-therapies/22.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/interviews/regulating-medicines-in-a-surge-of-change/15.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/march-2022-contents/531.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/pharmaceuticals/navigating-the-regulatory-landscape-for-regenerative-medicines-in-japan/19.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/main-navigation/brexit-the-regulatory-landscape-one-year-on/10.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/veterinary/terrestrial-ecotoxicological-studies-for-veterinary-pharmaceuticals-in-livestock-dung-in-the-field-phase-ii-tier-a-and-beyond/8.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/main-navigation/the-dias-accelerating-cmc-workshop/9.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/main-navigation/the-eu-restriction-proposal-for-intentionally-added-microplastics-a-focus-on-solid-dosage-form-medicinal-products-and-food-supplements/6.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/medical-devices/electronic-leaflet-pilot-in-belgium-and-luxembourg-hospitals/7.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/main-navigation/planning-for-the-future-sustainable-medical-devices/5.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/interviews/the-national-competent-authorities-of-belgium-and-luxembourg-share-their-views-about-the-e-pil-pilot/11.article 2025-04-09T10:49:00.100Z https://www.regulatoryrapporteur.org/interviews/a-review-of-paediatric-development-challenges-fda-collaboration-and-future-trends/12.article 2024-02-14T14:37:41.613Z https://www.regulatoryrapporteur.org/editorials/the-future-of-pharmaceuticals-is-green/13.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-devices/practical-insights-into-the-recent-eu-mdr-framework/80.article 2024-02-14T14:38:45.373Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/gene-therapy-products-regulatory-expectations-and-challenges-for-industry/79.article 2024-02-14T14:38:45.373Z https://www.regulatoryrapporteur.org/regulatory-procedures/amgens-experience-of-global-expedited-regulatory-pathways-in-the-development-of-sotorasib-part-1/87.article 2024-02-14T14:38:45.373Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/regulatory-framework-for-platform-technologies/84.article 2024-02-14T14:38:45.373Z https://www.regulatoryrapporteur.org/pharmaceuticals/a-regulatory-view-on-the-change-management-process-for-medicinal-products/74.article 2024-02-14T14:38:45.373Z https://www.regulatoryrapporteur.org/pharmaceuticals/cmc-considerations-for-us-biosimilars-development/83.article 2025-09-17T11:09:07.410Z https://www.regulatoryrapporteur.org/may-2022-contents/526.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/editorials/cmc-acceleration-is-driven-by-a-scientific-revolution/77.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/veterinary/procedure-withdrawals-within-europe-past-trends-impact-and-communication-recommendations/85.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/10-years-of-pharmacovigilance-legislation-the-perspective-of-a-national-agency/38.article 2024-02-14T14:39:20.010Z https://www.regulatoryrapporteur.org/editorials/how-regulators-are-navigating-the-evolving-pharmacovigilance-landscape/91.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-february-2022/89.article 2024-02-24T14:47:50.320Z https://www.regulatoryrapporteur.org/combination-products/what-can-past-decision-making-data-tell-us-about-how-the-fda-will-make-future-combination-product-categorisation-decisions/92.article 2024-02-14T14:39:20.010Z https://www.regulatoryrapporteur.org/pharmaceuticals/exploring-amgens-project-orbis-experience-with-sotorasib-part-2/90.article 2024-02-14T14:39:20.010Z https://www.regulatoryrapporteur.org/interviews/evolutions-in-patient-healthcare-at-mhra/93.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/interviews/updates-to-quality-legislation-from-the-ema/94.article 2024-02-14T14:39:20.010Z https://www.regulatoryrapporteur.org/cpd-supplements/the-olaratumab-experience/104.article 2024-01-02T14:43:41.297Z https://www.regulatoryrapporteur.org/cpd-supplements/regulatory-complexities-and-challenges-of-biosimilars/114.article 2024-01-02T14:48:05.540Z https://www.regulatoryrapporteur.org/editorials/a-new-era-of-digital-and-data-driven-innovations/116.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/interviews/digital-and-data-driven-information-management-at-the-ema/119.article 2024-02-14T14:39:51.357Z https://www.regulatoryrapporteur.org/regulatory-procedures/data-governance-as-a-strategic-imperative-for-regulatory-compliance/118.article 2024-02-14T14:39:51.357Z https://www.regulatoryrapporteur.org/pharmaceuticals/part-1-eu-reclassification-rx-to-otc-switch-regulatory-framework-what-are-the-key-challenges-for-industry-and-how-might-these-be-overcome/122.article 2024-02-14T14:39:51.357Z https://www.regulatoryrapporteur.org/software/translating-digitalisation-trends-into-tangible-solutions/123.article 2024-02-14T14:39:51.357Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/antibiotics-in-biopharmaceutical-production/124.article 2024-05-22T15:27:31.987Z https://www.regulatoryrapporteur.org/medical-devices/one-year-experience-on-eu-medical-devices-regulation-mdr-2017/745-for-single-integral-drug-device-combination-products/125.article 2024-02-14T14:39:51.357Z https://www.regulatoryrapporteur.org/privacy-policy 2025-05-30T08:17:00.573Z https://www.regulatoryrapporteur.org/cpd-supplements/fda-meetings-how-to-hold-a-successful-meeting-across-the-drug-development-lifecycle/132.article 2025-08-08T11:33:07.003Z https://www.regulatoryrapporteur.org/future-focus-topics 2026-02-26T11:25:54.137Z https://www.regulatoryrapporteur.org/july/august-2022-contents/522.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/regulatory-procedures/the-changing-role-of-regulatory-operations/139.article 2024-05-15T10:00:11.200Z https://www.regulatoryrapporteur.org/pharmaceuticals/streamlining-regulatory-processes-when-implementing-new-rims/140.article 2024-02-14T14:40:19.630Z https://www.regulatoryrapporteur.org/regulatory-procedures/harmonising-regulation-of-medicinal-allergen-products-throughout-the-european-union-the-historic-situation-and-subsequent-cmdh-guidance/141.article 2024-02-14T14:40:19.630Z https://www.regulatoryrapporteur.org/editorials/regulatory-operations-evolution-and-revolution/142.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/regulatory-procedures/how-data-remediation-and-stewardship-is-becoming-a-standard-responsibility-for-regulatory-operations-professionals/144.article 2024-02-14T14:40:19.630Z https://www.regulatoryrapporteur.org/pharmaceuticals/eu-reclassification-rx-to-otc-switch-regulatory-framework-what-are-the-key-challenges-for-industry-and-how-might-these-be-overcome-part-2/145.article 2024-02-14T14:40:19.630Z https://www.regulatoryrapporteur.org/clinical-trials/inclusion-of-older-people-in-drug-development-and-clinical-trials-part-1/146.article 2024-02-14T14:40:19.630Z https://www.regulatoryrapporteur.org/medical-devices/the-new-uk-mdr-a-great-start-to-a-long-road-ahead/148.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/medical-devices/the-importance-of-subjective-and-qualitative-risk-management-for-medical-devices-regulation/149.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/medical-devices/eu-expert-panels-for-high-risk-devices-another-level-of-review/150.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/medical-devices/navigating-the-mdrs-heightened-surveillance-and-performance-requirements/151.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/pharmaceuticals/inclusion-of-older-people-in-drug-development-and-clinical-trials-part-2/152.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-health-economics-profile-of-new-pharmaceuticals/153.article 2024-02-14T14:41:38.970Z https://www.regulatoryrapporteur.org/editorials/great-expectations-for-medical-technologies/154.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/october-2022-contents/396.article 2024-09-17T16:55:09.697Z https://www.regulatoryrapporteur.org/pharmaceuticals/us-fda-cder-and-cber-guidance-of-interest/161.article 2024-02-14T14:42:44.283Z https://www.regulatoryrapporteur.org/the-power-of-collaboration/162.article 2024-02-14T14:42:44.283Z https://www.regulatoryrapporteur.org/editorials/adapting-transforming-and-innovating/163.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-device-standards-update-september-2022/156.article 2024-02-24T14:47:38.090Z https://www.regulatoryrapporteur.org/pharmaceuticals/breakthrough-therapy-designation-from-serious-diseases-to-opioid-crisis-prevention/157.article 2024-02-14T14:42:44.283Z https://www.regulatoryrapporteur.org/regulatory-procedures/health-canada-regulatory-highlights-2021-2022/158.article 2024-02-14T14:42:44.283Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-worldwide-acceptance-of-non-legalised-ecpps/160.article 2024-02-14T14:42:44.283Z https://www.regulatoryrapporteur.org/november-2022-contents/395.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/september-2022-contents/397.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/main-navigation/vm5-cvmp-guidelines-update-data-protection-article-405-prescription-status-article34-and-benefit-risk/177.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/vm4-regulatory-update-and-perspectives-variations-packaging-and-labelling-pharmacovigilance/176.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/vm3-antimicrobials-the-new-rules-their-impact-and-consequences/175.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/vm2-novel-therapies-in-animal-health-balancing-guidance-versus-gaining-flexibility/174.article 2024-04-05T07:33:41.327Z https://www.regulatoryrapporteur.org/main-navigation/vm1-availability-and-innovation-under-a-new-vmp-legislation/173.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/md5-how-to-maintain-your-medical-device-on-the-market-and-fulfil-ongoing-obligations-in-the-post-launch-phase/181.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/md4-challenges-and-opportunities-for-small-companies-and-start-ups/180.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/md3-clinical-investigation-from-a-virtual-setting-perspective/179.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/md2-how-to-approach-artificial-intelligence-and-cybersecurity-now-and-in-the-future/178.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/ivd3-ivdr-for-small-companies-and-start-ups/184.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/ivd2-clinical-performance-evaluation-challenges/183.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/ivd1-current-state-and-update-on-ivdr-implementation/182.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/hm9-strategy-under-uncertainty-improving-the-odds-of-regulatory-success/172.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/hm8-the-present-and-future-of-developing-and-commercialising-cell-and-gene-therapies-in-a-global-world/171.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/hm7-are-patients-the-missing-piece-in-the-global-drug-development-puzzle/170.article 2025-03-14T09:49:51.797Z https://www.regulatoryrapporteur.org/main-navigation/hm6-innovation-in-regulatory-science-the-path-from-data-to-evidence-and-the-promise-to-streamline-the-regulatory-lifecycle/169.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/hm5-digital-health-opportunities-and-advancements-in-healthcare/168.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/hm4-assessing-the-value-of-innovative-therapies-trends-challenges-and-learnings/167.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/hm3-lessons-learned-and-strategic-priorities/166.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/hm2-are-expedited-programmes-delivering-on-the-promise-to-accelerate-drug-development-and-patient-access/165.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/meetings-reports/hm1-a-decade-of-innovative-clinical-trials-what-have-we-learned-and-where-are-we-going/164.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/main-navigation/topra-annual-lecture-access-to-medicines-beyond-europe-the-potential-of-reliance/185.article 2024-02-14T14:43:10.300Z https://www.regulatoryrapporteur.org/editorials/waltzing-into-change-in-vienna-the-regulatory-future-comes-into-focus/187.article 2024-04-30T14:55:37.537Z